Clinical Trials Logo

Focal Lipoid Glomerulosclerosis clinical trials

View clinical trials related to Focal Lipoid Glomerulosclerosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT00065611 Completed - Nephrosis Clinical Trials

Steroid Treatment for Kidney Disease

Start date: July 2003
Phase: Phase 3
Study type: Interventional

Focal segmental glomerulosclerosis (FSGS) and minimal change disease are kidney diseases that are associated with increased excretion of protein in the urine. Approximately half of FSGS patients will lose kidney function within 8 years of diagnosis and will require dialysis. The purpose of this study is to determine whether intermittent oral steroid therapy can cause sustained remission of FSGS and MCD. Approximately 70 participants, including adults and children older than age 2, will be enrolled in this study. They will receive 48 doses of oral dexamethasone over a period of 48 weeks. One group will take two daily doses every 2 weeks; the other group will take four daily doses every 4 weeks. Doctors will monitor participants before, during, and after the steroid treatment with extensive exams and testing. At the completion of the study, researchers will evaluate the safety and efficacy of the drug treatment.